Researchers isolated a molecule that may be under-produced in the guts of patients
Researchers at the Weizmann Institute of Science have shown in mice that intestinal microbes, collectively termed the gut microbiome, may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. As reported today in Nature,progression of an ALS-like disease was slowed after the mice received certain strains of gut microbes or substances known to be secreted by these microbes. Preliminary results suggest that the findings on the regulatory function of the microbiome may be applicable to human patients with ALS.
“Our long-standing scientific and medical goal is to elucidate the impact of the microbiome on human health and disease, with the brain being a fascinating new frontier,” says Prof. Eran Elinav of the Immunology Department. His team performed the study together with that of Prof. Eran Segal of the Computer Science and Applied Mathematics Department. Segal elaborates: “Given increasing evidence that microbiome affects brain function and disease, we wanted to study its potential role in ALS.” The study was led by postdoctoral fellows Drs. Eran Blacher and Stavros Bashiardes, and by staff scientist Dr. Hagit Shapiro, all in the Elinav lab. They collaborated with Dr. Daphna Rothschild, a postdoctoral fellow in Eran Segal’s lab, and Dr. Marc Gotkine, Head of the Motor Neuron Disease Clinic at Hadassah Medical Center, as well as with other scientists from Weizmann and elsewhere.
The scientists started out demonstrating in a series of experiments that the symptoms of an ALS-like disease in transgenic mice worsened after these mice were given broad-spectrum antibiotics to wipe out a substantial portion of their microbiome. In addition, the scientists found that growing these ALS-prone mice in germ-free conditions (in which, by definition, mice carry no microbiome of their own), is exceedingly difficult, as these mice had a hard time surviving in the sterile environment. Together, these results hinted at a potential link between alterations in the microbiome and accelerated disease progression in mice that were genetically susceptible to ALS.
Next, using advanced computational methods, the scientists characterized the composition and function of the microbiome in the ALS-prone mice, comparing them to regular mice. They identified 11 microbial strains that became altered in ALS-prone mice as the disease progressed or even before the mice developed overt ALS symptoms. When the scientists isolated these microbial strains and gave them one by one – in the form of probiotic-like supplements – to ALS-prone mice following antibiotic treatment, some of these strains had a clear negative impact on the ALS-like disease. But one strain, Akkermansia muciniphila, significantly slowed disease progression in the mice and prolonged their survival.
To reveal the mechanism by which Akkermansia may be producing its effect, the scientists examined thousands of small molecules secreted by the gut microbes. They zeroed in on one molecule called nicotinamide (NAM): Its levels in the blood and in the cerebrospinal fluid of ALS-prone mice were reduced following antibiotic treatment and increased after these mice were supplemented with Akkermansia, which was able to secrete this molecule. To confirm that NAM was indeed a microbiome-secreted molecule that could hinder the course of ALS, the scientists continuously infused the ALS-prone mice with NAM. The clinical condition of these mice improved significantly. A detailed study of gene expression in their brains suggested that NAM improved the functioning of their motor neurons.
One strain significantly slowed disease progression in the mice and prolonged their survival
Finally, the researchers examined the microbiome and metabolite profiles of 37 human ALS patients and compared them to those of family members sharing the same household. A detailed genomic analysis suggested that the gut microbiomes of ALS patients were distinct in composition and functional features from those of healthy controls. In particular, numerous microbial genes involved in the synthesis of NAM were significantly suppressed in ALS patients. An analysis of thousands of small molecules in the blood also revealed a distinct pattern in ALS patients as compared to controls. Here too, many of the intermediary molecules involved in the NAM synthesis were altered in the blood of ALS patients. When the researchers tested the levels of NAM itself, they found these to be significantly reduced in both the blood and the brain of 60 human ALS patients as compared to controls. Moreover, there was a correlation between reduced NAM levels and the degree of muscle weakness in the patients.
“These findings are only a first step towards achieving a comprehensive understanding of the potential impact of the microbiome on ALS,” Elinav says, “but they suggest that in the future, various means of altering the microbiome may be harnessed for developing new therapeutic options for ALS.”
Learn more: Gut Microbes May Affect the Course of ALS
The Latest on: Amyotrophic lateral sclerosis
via Google News
The Latest on: Amyotrophic lateral sclerosis
- ALS fishing tournament goes virtual due to viruson May 10, 2020 at 4:15 am
Kolar Toyota ALS Fishing Tournament will be held as scheduled on May 30. But instead of bringing together 300 or more anglers to compete on Island Lake near Duluth, anglers can fish anywhere they want ...
- Former Cabot teacher finds joy amid ALS diagnosison May 9, 2020 at 10:00 pm
The month of May is ALS Awareness Month. A few years ago, an ice-bucket challenge brought awareness to the disease, but support is still needed.
- Farmingdale Mom Battling ALS Encourages Social Media Challengeon May 8, 2020 at 1:36 pm
The 40-year-old mom of three has Lou Gehrig's disease but hopes a social media challenge raises awareness for an in-progress therapy.
- Am I eligible for Medicare under 65 years of age?on May 8, 2020 at 10:10 am
People often qualify for Medicare by reaching 65 years of age. However, people with some disabilities and chronic conditions can qualify early. Read more.
- Penn researchers discover key mechanism of cytokine storm in Castleman diseaseon May 7, 2020 at 1:04 pm
Penn researchers discover what is happening at the cellular level when Castleman patients experience a cytokine storm.
- Resilience to ALS Due to Synaptic Safety Mechanismon May 6, 2020 at 5:34 pm
UCSF researchers have identified a powerful self-corrective mechanism within synapses that is activated by neurodegeneration and acts to slow down disease progression in animal models of ALS.
- Proteomics-Based Approach Identifies Altered ER Domain Properties by ALS-Linked VAPB Mutationon May 6, 2020 at 2:13 am
An ER transmembrane protein, vesicle-associated membrane protein-associated protein B (VAPB), binds to several organelle-resident membrane proteins to mediate ER-organelle tethering. Mutation in ...
- Scientists gain new insight into the pathological mechanisms behind two neurodegenerative diseaseson May 6, 2020 at 12:28 am
An international team led by Emory scientists has gained insight into the pathological mechanisms behind two devastating neurodegenerative diseases.
- Genetic doppelgaengers: Research provides insight into two neurological puzzleson May 5, 2020 at 11:08 am
An international team led by Emory scientists has gained insight into the pathological mechanisms behind two devastating neurodegenerative diseases. The scientists compared the most common inherited ...
- How AI can help diagnose neurological diseaseon May 5, 2020 at 9:00 am
A retinal scan and AI can detect tiny eye movements that can help diagnose and treat difficult neural disorders much earlier than before.
via Bing News